Schonfeld Strategic Advisors LLC Chemo Centryx, Inc. Transaction History

Schonfeld Strategic Advisors LLC

$13.8 Billion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $7.3 Million - $17.1 Million	329,252 Added 695.64%	376,583 $19.5 Million
Q2 2022 Aug 15, 2022	BUY	$15.36 - $27.51 $727,004 - $1.3 Million	47,331 New	47,331 $1.17 Million
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $166,650 - $293,400	-7,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $137,850 - $303,750	7,500 New	7,500 $273,000
Q4 2020 Feb 16, 2021	SELL	$47.25 - $65.16 $688,479 - $949,446	-14,571 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$46.35 - $61.69 $181,228 - $241,207	3,910 Added 36.68%	14,571 $798,000
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $411,301 - $693,711	10,661 New	10,661 $614,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.